Pharmacodynamic and pharmacokinetic drug interactions reported to VigiBase, the WHO global individual case safety report database

European Journal of Clinical Pharmacology

Volumn 67, Issue 6, 2011, Pages 633-641

  Strandell, Johanna ^a,b   Wahlin, Stina ^c  

^a UPPSALA MONITORING CENTRE   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Additive effects; Enzyme inhibition; Pharmacovigilance; VigiBase

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; CARBAMAZEPINE; CELECOXIB; CERIVASTATIN; CLARITHROMYCIN; CLOPIDOGREL; CYTOCHROME P450; DICLOFENAC; DIGOXIN; ENOXAPARIN; FLUINDIONE; FUROSEMIDE; GEMFIBROZIL; HEPARIN; ISONIAZID; LAMOTRIGINE; MICONAZOLE; PHENYTOIN; RIFAMPICIN; ROXITHROMYCIN; SIMVASTATIN; SPIRONOLACTONE; VALPROIC ACID; WARFARIN;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ANEMIA; ARTICLE; BRADYCARDIA; BRAIN HEMORRHAGE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG INHIBITION; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; ENZYME INHIBITION; FEVER; GASTROINTESTINAL HEMORRHAGE; HEMATOMA; HEMATURIA; HEPATITIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; JAUNDICE; MEDICAL LITERATURE; MELENA; NAUSEA; PATIENT SAFETY; PRIORITY JOURNAL; PURPURA; REFERENCE DATABASE; RHABDOMYOLYSIS; SIDE EFFECT; STEVENS JOHNSON SYNDROME; VOMITING; WORLD HEALTH ORGANIZATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DATABASES, FACTUAL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; DRUG TOXICITY; FEMALE; HUMANS; MALE; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGICAL PHENOMENA; PHARMACOVIGILANCE; POLYPHARMACY; RISK; WORLD HEALTH ORGANIZATION;

EID: 79959726851     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-010-0979-y     Document Type: Article

References (32)

1. Johnell K, Klarin I (2007) The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600, 000 elderly patients from the Swedish Prescribed Drug Register. Drug Saf 30(10):911-918 (Pubitemid 47481446)
2. Leone R, Magro L, Moretti U, Cutroneo P, Moschini M, Motola D et al (2010) Identifying adverse drug reactions associated with drug-drug interactions: data mining of a spontaneous reporting database in Italy. Drug Saf 33(8):667-675
3. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ et al (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. Br Med J 329(7456):15-19 (Pubitemid 38869995)
4. Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M (2009) Adverse drug reactions in hospital inpatients: a prospective analysis of 3695 patient-episodes. PLoS ONE 4(2):e4439
5. Griffin JP, D'Arcy PF (1997) A manual of adverse drug Interactions, 5th edn. Elsvier Science, Amsterdam
6. Edwards IR, Olsson S (2002) In the WHO International Drug Monitoring Programme. In: Aronson JK (ed) Side effects of drugs, annual volume no. 25: Elsevier Science, Amsterdam, pp 589-598
7. Lindquist M (2008) VigiBase, the WHO Global ICSR Database System: basic facts. Drug Inf J 42(5):409-419
8. Baxter K (ed) (2006) Stockley's drug interactions, 7th edn. Pharmaceutical Press, London
9. Pirmohamed M, Orme ML'E (1998) Drug interactions of clinical importance. In: Davies DM, Ferner RE, de Glanville H (eds) Davies's textbook of adverse drug reactions, 5th edn. (pp. 888- 912) Chapman & Hall, London
10. Stockley's Drug Interaction. Medicines Complete. Accessed 5 Feb to 19 Mar 2010. Available at: https://www.medicinescomplete.com/mc/login.htm
11. FASS for health care professionals. Läkemedelsindustrifö reningen. Accessed from February to November 2010. Available at: http://www.fass.se/LIF/home/index.jsp?UserTypeID=0
12. DrugDex. Thomson Reuters Healthcare MICROMEDEX. Accessed from February to November 2010. Available at: http://www.thomsonhc.com/home/
13. PubMed. National Centre for Biotechnology Information. Accessed 5 Feb to 19 Mar 2010. Available at: http://www.ncbi.nlm.nih.gov/pubmed/
14. Horn JR, Hansten PD, Chan LN (2007) Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 41 (4):674-680 (Pubitemid 46625492)
15. MedDRA term selection points to consider. Accessed: 26 Jan 2010. Available at: http://www.meddramsso.com
16. Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D et al (1995) Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA 274(1):29-34
17. Cullen DJ, Sweitzer BJ, Bates DW, Burdick E, Edmondson A, Leape LL (1997) Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units. Crit Care Med 25(8):1289-1297 (Pubitemid 27347291)
18. Wiholm B-E, Olsson S, Moore N, Waller P (2000) In Spontaneous reporting systems outside the US. In: Strom B (ed) Pharmacoepidemiology, 3rd edn. Wiley, Chichester, pp 175-192
19. Edwards IR, Biriell C (1994) Harmonisation in pharmacovigilance. Drug Saf 10(2):93-102 (Pubitemid 24045719)
20. Yue QY, Strandell J, Myrberg O (2006) Concomitant use of glucosamine potentiates the effect of warfarin. Drug Saf 29 (10):911-1010
21. Knudsen JF, Sokol GH (2008) Potential glucosamine-warfarin interaction resulting in increased international normalized ratio: case report and review of the literature and MedWatch database. Pharmacotherapy 28(4):540-548 (Pubitemid 351466466)
22. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P (2002) St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 54(4):349-356 (Pubitemid 35334946)
23. Johansson K, Olsson S, Hellman B, Meyboom RH (2007) An analysis of Vigimed, a global e-mail system for the exchange of pharmacovigilance information. Drug Saf 30(10):883-889 (Pubitemid 47481443)
24. Meyboom R (1998). Detecting adverse drug reactions, pharmacovigilance in Netherlands. PhD thesis. Catholic University of Nijmegen, Nijmegen
25. Fridén S (2009) Gender differences in international adverse drug reaction surveillance. MSc thesis. Uppsala University, Uppsala
26. Strandell J, Bate A, Lindquist M, Edwards IR, Database SFINX (2008) Drug-drug interactions - a preventable patient safety issue? Br J Clin Pharmacol 65(1):144-146
27. Yamreudeewong W, DeBisschop M, Martin LG, Lower DL (2003) Potentially significant drug Interactions of class III antiarrhythmic drugs. Drug Saf 26(6):421-438 (Pubitemid 36560714)
28. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ (2002) Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 72(6):685-691 (Pubitemid 36021007)
29. Neuvonen PJ, Niemi M, Backman JT (2006) Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 80(6):565-581 (Pubitemid 44908269)
30. Shitara Y, Sugiyama Y (2006) Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 112(1):71-105 (Pubitemid 44301483)
31. Law M, Rudnicka AR (2006) Statin safety: a systematic review. Am J Cardiol 97:52 C-60 C
32. Hachad H, Ragueneau-Majlessi I, Levy RH (2002) New antiepileptic drugs: review on drug interactions. Ther Drug Monit 24(1):91-103 (Pubitemid 34110441)